Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB-DART-NK01 in Relapsed/Refractory Small Cell Lung Cancer
NCT07744256Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
A Phase 2 trial of EB-DART-NK01 in small cell lung cancer (SCLC), sponsored by Biotech Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
EB-DART-NK01
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07744256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07744256.